Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the leader in those markets. That honor belongs to Novo Nordisk (NYSE: NVO), which sells the blockbuster drugs Ozempic and Wegovy for treating diabetes and obesity,

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.